论文信息 - Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial - 字舞流文

Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial

E. Braunwald | C. Bode | M. Tendera | C. Gibson | C. Gibson | F. Verheugt | A. Plotnikov | P. Burton | Y. Daaboul | S. Korjian | P. Jain | Purva Jain | Serge Korjian